Analyst: GN Hearing divestment could still be in the cards after new capital plan

Danske Bank assesses that GN’s plan to control its debt will yield a strong negotiation position, should the company wish to explore a divestment of its hearing aid division.

For subscribers

DNB: GN could hit long-term debt-gearing target in 2025

For subscribers

Demant is fighting tooth and nail to get rid of its surgical division

Demant proposes partial Oticon Medical divestment to ease competition concerns

For subscribers

According to GN, there has only been few cases of infection in the company's market organization | Photo: Pr

GN considers Covid-19 situation far less critical than six months ago

For subscribers

Cochlear sees no other suitors for Demant's implants business

For subscribers

Gitte Aabo, CEO of GN | Foto: Gn Hearing / Pr

GN CEO on new capital plan: "You should always have a plan B"

For subscribers

New GN capital plan removes some stock risks, assesses bank
The focus will now return to the hearing company’s underlying business, says Jyske Bank in an analysis.
For subscribers
Analyst: Share sale doesn't solve all of GN's debt problems
GN’s capital raise could be described as a partial solution that does not resolve hearing company’s debt issues entirely, according to ABG Sundal Collier analyst.
For subscribers
GN completes DKK 2.7bn capital raise
A directed share issue saw 17.3 million GN shares sold, of which 13.7 million were new issues.
For subscribers
Analysts raise expectations for Demant significantly after guidance upgrade
Demant’s upward adjustments are making analysts raise their expectations for the hearing aid manufacturer.
For subscribers
Novo Nordisk Foundation taps Demant's legal chief
Pelle Munk-Poulsen bids the hearing aids manufacturer farewell after a decade as the helm of the legal department, which has grown substantially over the years.
For subscribers
Hearing industry supplier delivers its best financial result citing pent-up pandemic demand
Estron’s top and bottom lines have shot up in 2022 but the current financial year will be more subdued.
For subscribers
Analysts turn up hopes for GN Hearing following first quarter
GN Hearing is now forecasted to reach 8.6% organic growth in 2023.
For subscribers
Analyst: Subdued prognosis from Sonova after non-renewal of contract
During the fiscal year 2022/23, Sonova lost a significant client in the US as their contract was not renewed. The prognosis for the coming year will be affected as such, estimates Sydbank analyst
For subscribers
Sonova held back due to loss of Costco contract
The Swiss hearing aid manufacturer describes losing one of its ”largest customers in the US” while noting a general deceleration of the pace of the US market.
For subscribers
Sonova forecasts growth next fiscal year despite short-term uncertainties
In the financial year of 2023/2024, Sonova expects revenue growth of 3–7%.
For subscribers
Sonova beats back, regains veterans market shares in April
The Swiss company now has its biggest slice of the hearing aid market for US veterans since October.
For subscribers
President of Demant subsidiary Interacoustics resigns
Demant will neither confirm nor deny a link to the whistleblower case that has cost three leading employees their jobs, including at an unnamed subsidiary.
For subscribers
WS Audiology CEO doesn't feel bested by competitors despite lower growth
Rivals have delivered two-digit organic growth rates, but WSA’s totaled at 9% in its recent quarter. However, this does not mean that the company has done any worse, posits CEO Eric Bernard.
For subscribers
WSA raises full-year expectations
Like competitors Demant and GN, WS Audiology sees a bright future ahead.
For subscribers
Demant sees multiple scenarios for divesting surgical division
However, it’s too soon to speculate in concrete outcomes before authorities finish their evaluations of whether Demant’s divestment of Oticon Medical is anti-competitive, says CEO.
For subscribers
Demant stays mute on leadership layoffs: "We have issues and we’re dealing with it"
Søren Nielsen, CEO of Demant, is tight-lipped on why he fired an executive and two leading employees last week.
For subscribers
Demant CEO: Prognosis held back by uncertainty about momentum's duration
Demant’s first-quarter success was partially due to the launch of flagship product Oticon Real, which created particular interest among hearing aid users.
For subscribers
Demant could easily reach its highest expectations, assesses analyst
One analyst already sees a chance of the hearing firm going beyond its recently upgraded full-year guidance.
For subscribers
Demant confirms grand growth in wholesale segment after recent upgrade
Demant CEO Søren Nielsen points to the company’s new flagship product, Oticon Real, as a contributing factor for driving the business area of Hearing Aids.
For subscribers
Factors behind Demant upgrade to attract attention in imminent first-quarter report
”We expect to see more nuances about the development of the quarter and prerequisites for the new full-year prognosis,” says an analyst anticipating Demant’s report on Wednesday.
For subscribers